| Deng, Yanhong |
OPTICAL, NCT02572141: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Active, not recruiting | 3 | 738 | RoW | Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens, Oxaliplatin, 5-Fluorouracil, Capecitabine, Leucovorin, Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens | Sun Yat-sen University | Colon Cancer | 04/21 | 04/23 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
TRIBE-C, NCT04230187: Bevacizumab Plus MFOLFOXIRI As First-line Treatment for Patients with Unresectable Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | mFOLFOXIRI plus Bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, mFOLFOX6 Plus Bevacizumab | Yanhong Deng | Colorectal Cancer | 01/24 | 06/26 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
FOBEAR, NCT04215731: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer |
|
|
| Recruiting | 3 | 500 | RoW | Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, Restaging, Concomitant Chemoradiotherapy, Surgery, Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging), Induction chemotherpay with FOLFOX | Yanhong Deng | Rectal Cancer | 02/26 | 02/26 | | |
| Recruiting | 3 | 638 | RoW | mFOLFOXIRI adjuvant chemotherapy, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil, mFOLFOX6 adjuvant chemotherapy | Sun Yat-sen University | Colorectal Cancer | 02/25 | 02/25 | | |
AFFORD, NCT05427669: Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 340 | NA | mFOLFOXIRI, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, mFOLFOX6 | Yanhong Deng | Colorectal Cancer | 07/25 | 07/27 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT05130021: A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 130 | RoW | MAX-40279-01, regorafenib | Maxinovel Pty., Ltd. | Metastatic Colorectal Cancer | 05/22 | 10/23 | | |
PCOX, NCT03638297: PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer |
|
|
| Recruiting | 2 | 29 | RoW | PD-1 antibody + cox inhibitor | Sun Yat-sen University | Colorectal Cancer | 08/22 | 08/25 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT04030260: Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Regorafenib and PD-1 antibody in Combination with Radiotherapy, Regorafenib, PD-1 antibody, Radiation therapy | Sun Yat-sen University | Colorectal Cancer Metastatic, MSS | 02/23 | 07/23 | | |
PICC, NCT03926338: Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 150 | RoW | Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months, Toripalimab, Celecoxib, Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months, Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months, Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months | Sun Yat-sen University | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 04/27 | 04/30 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
SINCERE, NCT05933980: Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 44 | RoW | Rego+Tori+Cele, Bayer AG, Innovent Biologics | Sun Yat-sen University | Colorectal Cancer, Liver Metastases, MSS | 09/25 | 12/25 | | |
| Recruiting | 2 | 23 | RoW | Dostarlimab, GSK4057190A, TSR-042 | GlaxoSmithKline | Neoplasms, Rectal | 12/28 | 03/31 | | |
NCT05472948: Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | Surufatinib, SULANDA, Sintilimab, IBI308, Capecitabine, Capecitabine tablets | Sun Yat-sen University | Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic | 11/24 | 11/25 | | |
| Recruiting | 2 | 52 | RoW | Tislelizumab + Capecitabine, Best supportive care | Yanhong Deng | Metastatic Colorectal Cancer，NED | 02/25 | 11/27 | | |
OPTICAL-2, NCT05571644: Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 143 | RoW | mFOLFOXIRI + Cadonilimab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Cadonilimab (AK104), mFOLFOX6, mFOLFOXIRI | Sun Yat-sen University | Colorectal Cancer | 12/24 | 12/25 | | |
DETECT, NCT05578287: RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 29 | RoW | Anti-HER2 ADC, Disitamab Vedotin, Tislelizumab, Capecitabin, Celecoxib | Sun Yat-sen University | Colorectal Cancer | 12/24 | 12/25 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CEIL, NCT05959356: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 198 | RoW | Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab or c225, Envafolimab, Irinotecan, Oxaliplatin, Leucovorin, 5-FU, Cetuximab + mFOLFOX6/FOLFIRI | Sun Yat-sen University | Metastatic Colorectal Cancer | 12/25 | 12/27 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05775900: Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer |
|
|
| Recruiting | 1/2 | 24 | RoW | Cetuximab, Erbitux, Capecitabine, Capecitabine Tablets | Sun Yat-sen University | Metastatic Colorectal Cancer | 12/24 | 12/24 | | |
| Not yet recruiting | 1/2 | 74 | RoW | Liposomal irinotecan, Bevacizumab, avastin | Sun Yat-sen University | Colorectal Cancer | 06/25 | 07/26 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 28 | RoW | Cadonilimab | Sun Yat-sen University | Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) | 07/25 | 07/27 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT04930354: ECP-1014 Treatment for Patients With Solid Tumor Cancers |
|
|
| Recruiting | 1 | 29 | RoW | ECP-1014, GIBH-1014 | Euclises Pharmaceuticals, Inc. | Solid Tumor | 09/23 | 12/23 | | |
| Recruiting | 1 | 60 | RoW | SG1906 | Hangzhou Sumgen Biotech Co., Ltd. | Locally Advanced Unresectable or Metastatic Solid Tumors | 02/25 | 08/25 | | |
NCT06036862: Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis |
|
|
| Recruiting | N/A | 50 | RoW | Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction | Sun Yat-sen University | Anastomotic Stenosis | 12/26 | 12/26 | | |
NCT06043999: Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients |
|
|
| Recruiting | N/A | 392 | RoW | Radical total mesorectal excision, Salavge Adjuvant Chemoradiotherapy | Sun Yat-sen University | Chemotherapy Effect, Rectal Cancer | 12/28 | 12/28 | | |
| Gao, Xiang |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
NCT05770609: A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | SPH3127 Tablets with Dose A, SPH3127 Tablets with Dose B, SPH3127 Tablets placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Mild to Moderate Ulcerative Colitis | 02/25 | 02/25 | | |
| Recruiting | N/A | 174 | RoW | Upadacitinib | Xiang Gao | Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | 12/28 | 12/28 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
| Recruiting | N/A | 1050 | RoW | Biologics | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease, Ulcerative Colitis | 11/24 | 11/24 | | |
